A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery Stenting

Martin B. Leon; Donald S. Baim; Jeffrey J. Popma; Paul Gordon; Donald E. Cutlip; Kalon K.L. Ho; Alex Giambartolomei; Daniel J. Diver; David Lasorda; David O. Williams; Stuart Pocock; Richard E. Kuntz

doi:10.1056/nejm199812033392303

Abstract

As compared with aspirin alone and a combination of aspirin and warfarin, treatment with aspirin and ticlopidine resulted in a lower rate of stent thrombosis, although there were more hemorrhagic complications than with aspirin alone. After coronary stenting, aspirin and ticlopidine should be considered for the prevention of the serious complication of stent thrombosis.

Keywords

MedicineAspirinTiclopidineWarfarinAntithromboticMyocardial infarctionInternal medicineStentAntiplatelet drugSurgeryThrombosisCardiologyClopidogrelAtrial fibrillation

MeSH Terms

AgedAngioplastyBalloonCoronaryAnticoagulantsAspirinCoronary DiseaseDrug TherapyCombinationFemaleHemorrhageHumansMaleMiddle AgedPlatelet Aggregation InhibitorsSingle-Blind MethodStentsThrombosisTiclopidineWarfarin

Affiliated Institutions

Related Publications

Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention

Shamir R. Mehta , Salim Yusuf

2003 Journal of the American College of Ca... 97 citations

Design of ESPRIT: An International Randomized Trial for Secondary Prevention after Non-Disabling Cerebral Ischaemia of Arterial Origin

E.L.L.M. De Schryver

The ESPRIT trial addresses the problem that aspirin, the standard therapy for secondary prevention of vascular complications after a transient ischaemic attack (TIA) or ischaemi...

2000 Cerebrovascular Diseases 98 citations

Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial Infarction

Shlomi Matetzky , Б. С. Шенкман , Victor Guetta +8 more

Background— Although clopidogrel reduces the risk of cardiovascular episodes after coronary events and stenting, a substantial number of incidents continue to occur. Methods and...

2004 Circulation 1352 citations

Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome

John H. Alexander , Renato D. Lópes , Stefan James +31 more

The addition of apixaban, at a dose of 5 mg twice daily, to antiplatelet therapy in high-risk patients after an acute coronary syndrome increased the number of major bleeding ev...

2011 New England Journal of Medicine 990 citations

Randomized Comparison of Prasugrel (CS-747, LY640315), a Novel Thienopyridine P2Y <sub>12</sub> Antagonist, With Clopidogrel in Percutaneous Coronary Intervention

Stephen D. Wiviott , Elliott M. Antman , Kenneth J. Winters +8 more

Background— Despite the current standard antiplatelet regimen of aspirin and clopidogrel (with or without glycoprotein IIb/IIIa inhibitors) in percutaneous coronary intervention...

2005 Circulation 378 citations

Publication Info

Year: 1998
Type: article
Volume: 339
Issue: 23
Pages: 1665-1671
Citations: 1805
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery Stenting

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1805

OpenAlex

Influential

1449

CrossRef

Cite This

APA Style

                            
                                
                                    Martin B. Leon, 
                                
                                    Donald S. Baim, 
                                
                                    Jeffrey J. Popma
                                
                                et al.
                            
                            (1998). 
                            A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery Stenting. 
                            New England Journal of Medicine
                            , 339
                            (23)
                            , 1665-1671.
                            https://doi.org/10.1056/nejm199812033392303
                        

Identifiers

DOI: 10.1056/nejm199812033392303
PMID: 9834303

Data Quality

Data completeness: 86%